Author: 1cBio, Inc.

1cBio Received Shareholder Proceeds Upon Closing of BioMarin Pharmaceutical Inc.’s Acquisition of Alesta Therapeutics

October 14, 2026
1cBio and Lee’s Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio’s PARP1 Inhibitor OC-3 for Oncology in Greater China and Southeast Asia

September 9, 2026

1cBio Received Shareholder Proceeds Upon Closing of BioMarin Pharmaceutical Inc.’s Acquisition of Alesta Therapeutics